LENSAR Return on Equity

LENSAR (LNSR) currently reports a ROE of 232.78%. That is above the Healthcare sector average of 21.28%. Use the charts on this page to explore LENSAR's ROE history and peer comparisons.

LENSAR's ROE of 232.78% is higher than the Healthcare sector average of 21.28%. That is roughly 993.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but LENSAR's current 232.78% should be judged against Healthcare norms (sector average: 21.28%) and against LNSR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 232.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for LENSAR, and consider following LNSR for alerts when major investors trade the stock.

LENSAR is classified in the Healthcare sector. On ROE, it currently shows 232.78% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LNSR with unrelated industries.